HSP70-14 Antibody

Definition and Target Specificity

The HSP70-14 antibody, often designated as cmHsp70.1, binds to a 14-mer peptide (AA450–463) within the oligomerization domain of HSP70 . Unlike other HSP70 antibodies, cmHsp70.1 selectively recognizes the membrane-localized form of HSP70 expressed on cancer cells, while sparing normal cells .

Key Features:

• Epitope: TKD peptide (TKDNNLLGRFELSG) .

• Cross-reactivity: Human and mouse tumors .

• Exclusivity: Does not bind cytosolic HSP70 or HSP70 in non-transformed cells .

Development and Validation

The cmHsp70.1 antibody was generated by immunizing mice with the TKD peptide . Validation studies confirmed:

• Specificity: Reactivity with memHsp70+ tumor cell lines (e.g., colon, breast, lung carcinomas, melanoma) but not healthy tissues .

• Sensitivity: Detects memHsp70 in 40–50% of primary human tumors, including metastases .

Table 1: Tumor Cell Reactivity of cmHsp70.1 Antibody

Tumor Targeting and Internalization

• The antibody binds memHsp70 on tumor cells, triggering rapid internalization via endosomal pathways .

• Co-localizes with mitochondrial membranes post-internalization, suggesting subcellular trafficking .

Immunomodulatory Effects

• NK Cell Activation: Enhances CD94 receptor density on natural killer (NK) cells, boosting tumor cytotoxicity .

• Pro-inflammatory Signaling: Binds Siglec-14 on monocytes, inducing TNFα and IL-8 secretion via NF-κB activation .

Imaging

• Enables in vivo tumor imaging by targeting memHsp70+ cells .

Antibody-Dependent Cellular Cytotoxicity (ADCC)

• Induces ADCC in memHsp70+ tumors, as demonstrated in murine models .

Combination Therapies

• Synergizes with recombinant granzyme B to induce apoptosis in tumor cells .

• Reduces Th17 cell populations in psoriasis models, suggesting anti-inflammatory applications .

Clinical Relevance

• Prognostic Marker: High memHsp70 levels correlate with tumor aggressiveness and metastatic potential .

• Therapeutic Target: Clinical trials are exploring cmHsp70.1-conjugated drugs for precision oncology .

Research Limitations

• Species Specificity: Siglec-14 interactions are human-specific, limiting rodent model applications .

• Heterogeneity: Not all tumors uniformly express memHsp70, necessitating patient stratification .